Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoimmunotherapy With Low-Dose Radiotherapy in Locally Advanced OSCC
NCT07028918Phase 1Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in oral squamous cell carcinoma (OSCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Complete Pathological Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07028918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028918.